Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial

Yardley, D. A.;Coleman, R.;Conte, P.;Cortes, J.;Brufsky, A.;Shtivelband, M.;Young, R.;Bengala, C.;Ali, H.;Eakel, J.;Schneeweiss, A.;De La Cruz-Merino, L.;Wilks, S.;O’Shaughnessy, J.;Glück, S.;Li, H.;Miller, J.;Barton, D.;Harbeck, N.

2018